Möchten Sie immer auf dem neuesten Stand bleiben?

BRIDGEWATER, N.J., May 04, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that clinical data demonstrating that use of the V-Go® Wearable Insulin Delivery Device...

BRIDGEWATER, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that the Company will host a conference call with clinical experts to discuss their...

BRIDGEWATER, N.J., May 01, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that multiple abstracts supporting its wearable insulin delivery technology have been...

BRIDGEWATER, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will release its first quarter 2017 financial results on Friday, May 12, 2017...

BRIDGEWATER, N.J., March 30, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced the publication of an article that highlights the benefit of diabetes medication delivery...

BRIDGEWATER, N.J., March 23, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (OTCQB:VLRX) today announced the pricing of its underwritten public offering of 5,250,000 shares of its common stock at...

BRIDGEWATER, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (OTCQB:VLRX) today announced that effective at 9:00 a.m., EDT, on March 15, 2017, the Company will effect an...

BRIDGEWATER, N.J., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (OTCQB:VLRX) today announced financial results for the fourth quarter and full year ended December 31, 2016. Fourth...

BRIDGEWATER, N.J., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (OTCQB:VLRX) today announced data showing greater reductions in A1c and insulin dose in patients with type 2 diabetes...

BRIDGEWATER, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (OTCQB:VLRX) today announced that it has reached agreement with both of its secured creditors (funds affiliated with CRG...